Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pivekimab Sunirine (IMGN632) in CD123+ Acute Myeloid Leukemia
NCT04086264Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2019
- Primary completion
- Feb 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 6
01
Overview
A Phase 2 trial of pivekimab sunirine in acute myeloid leukemia (AML), sponsored by AbbVie Inc.. Started Nov 2019; status: active, not recruiting.
02
Drugs
pivekimab sunirine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04086264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04086264.